Healthcare-associated infections due to carbapenemase-producing Enterobacteriaceae: Bacteriological profile and risk factors

Medecine et Maladies Infectieuses

Volumn 46, Issue 3, 2016, Pages 157-162

  Chabah, M ^a   Chemsi, M ^a   Zerouali, K ^a   Alloula, O ^a   Lehlimi, M ^a   Habzi, A ^a   Benomar, S ^a  

^a IBN ROCHD UNIVERSITY HOSPITAL   (Morocco)

Author keywords

Carbapenemase; Healthcare associated infection; Newborn

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMPICILLIN; CARBAPENEM; CEFOTAXIME; CEFOXITIN; CEFPODOXIME; CEFTAZIDIME; CEPHALOSPORIN; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; ERTAPENEM; GENTAMICIN; IMIPENEM; NETILMICIN; NORFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN; BACTERIAL PROTEIN; BETA LACTAMASE; CARBAPENEMASE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE; CASE CONTROL STUDY; CATHETER INFECTION; CONTROLLED STUDY; ENTEROBACTERIACEAE INFECTION; FEMALE; HEALTHCARE ASSOCIATED INFECTION; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MENINGITIS; NEWBORN; NONHUMAN; PEDIATRIC WARD; PNEUMONIA; PREVALENCE; RETROSPECTIVE STUDY; RISK FACTOR; URINARY TRACT INFECTION; ANTIBIOTIC RESISTANCE; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; CROSS INFECTION; DISEASE PREDISPOSITION; DRUG EFFECTS; ENTERIC FEEDING; ENZYMOLOGY; HOSPITAL; ISOLATION AND PURIFICATION; MICROBIOLOGY; MOROCCO; MULTIDRUG RESISTANCE; NEONATAL INTENSIVE CARE UNIT; PREMATURITY; STATISTICS AND NUMERICAL DATA;

BACTERIAL PROTEINS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; CASE-CONTROL STUDIES; CROSS INFECTION; DISEASE SUSCEPTIBILITY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTERAL NUTRITION; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HOSPITALS, PEDIATRIC; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; INTENSIVE CARE UNITS, NEONATAL; MALE; MOROCCO; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84958190999     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2015.12.015     Document Type: Article

References (33)

1. Conly J., et al. La NDM-1: summum de la résistance aux antimicrobiens. La Note mauve 2011, 33.
2. Yigit H., Queenan A.M., Anderson G.J., Domenech-Sanchez A., Biddle J.W., Steward C.D., et al. Novel carbapenem-hydrolyzing β-lactamase KPC-1 from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 2001, 45:1151-1161.
3. Archibald L., Phillips L., Monnet D., McGowan J.E., Tenover F., Gaynes R. Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit. Clin Infect Dis 1997, 24:211-215.
4. Foglia E.E., Fraser V.J., Elward A.M. Effect of nosocomial infections due to antibiotic-resistant organisms on length of stay and mortality in the pediatric intensive care unit. Infect Control Hosp Epidemiol 2007, 28:299-306.
5. Borer A., Saidel-Odes L., Riesenberg K., Eskira S., Peled N., Nativ R., et al. Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia. Infect Control Hosp Epidemiol 2009, 30:972-976.
6. Nordmann P. Carbapenemase-producing Enterobacteriaceae: overview of a major public health challenge. Med Mal Infect 2014, 44:51-56.
7. Munoz-Price L.S., Poirel L., Bonomo R.A., Schwaber M.J., Daikos G.L., Cormican M., et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 2013, 13:785-796.
8. Chemsi M., Chahid I., et al. Incidence des infections bacteriennes nosocomiales. Hôpital d'enfants Abderrahim Harouchi, CHU Ibn Rochd, Casablanca, Maroc. J Pediatr Puericult 2013, 26:11-18.
9. Paterson D.L., Bonomo R.A. Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev 2005, 18:657-686.
10. Nordmann P., Cuzon G., Naas T. The real threat of Klebsiella pneumonia carbapenemase producing bacteria. Lancet Infect Dis 2009, 9:228-236.
11. Lepelletier D., Batard E., Berthelot P., Zahar J.R., Lucet J.C., Fournier S., et al. Maîtrise de la diffusion des entérobactéries productrices de carbapénèmases: épidémiologie, stratégies de prévention et enjeux. Rev Med Interne 2015, 36:474-479.
12. Recommandations pour la prévention de la transmission croisée des « Bactéries hautement résistantes aux antibiotiques émergentes » (BHRe) 2014, Haut Conseil de la santé publique. Commission spécialisée sécurité patient. http://www.hcsp.fr/explore.cgi/avisrapportsdomaine?clefr=372.
13. Huang T.D., Berhin C., Bogaerts P., Glupczynski Y. Prevalence and mechanisms of resistance to carbapenems in Enterobacteriaceae isolates from 24 hospitals in Belgium. J Antimicrob Chemother 2013, 68:1832-1837. Multicentre study group.
14. Robert J., Pantel A., Mérens A., Lavigne J.P., Nicolas-Chanoine M.H. Incidence rates of carbapenemase-producing Enterobacteriaceae clinical isolates in France: a prospective nationwide study in 2011-2012. J Antimicrob Chemother 2014, 69:2706-2712. ONERBA's Carbapenem Resistance Study Group.
15. Miró E., Agüero J., Larrosa M.N., Fernández A., Conejo M.C., Bou G., et al. Prevalence and molecular epidemiology of acquired AmpC b-lactamases and carbapenemases in Enterobacteriaceae isolates from 35 hospitals in Spain. Eur J Clin Microbiol Infect Dis 2013, 32:253-259.
16. Mataseje L.F., Bryce E., Roscoe D., Boyd D.A., Embree J., Gravel D., et al. Carbapenem-resistant Gram-negative bacilli in Canada 2009-10: results from the Canadian Nosocomial Infection Surveillance Program (CNISP). J Antimicrob Chemother 2012, 67:1359-1367.
17. Gasink L.B., Edelstein P.H., Lautenbach E., Synnestvedt M., Fishman N.O. Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K pneumoniae. Infect Control Hosp Epidemiol 2009, 30:1180-1185.
18. Patel G., Huprikar S., Factor S.H., Jenkins S.G., Calfee D.P. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008, 29:1099-1106.
19. Kwak Y.G., Choi S.H., Choo E.J., Chung J.W., Jeong J.Y., Kim N.J., et al. Risk factors for the acquisition of carbapenem-resistant Klebsiella pneumoniae among hospitalized patients. Microb Drug Resist 2005, 11:165-169.
20. Calfee D., Jenkins S.G. Use of active surveillance cultures to detect asymptomatic colonization with carbapenem-resistant Klebsiella pneumoniae in intensive care unit patients. Infect Control Hosp Epidemiol 2008, 29:966-968.
21. Chagas T.P., Seki L.M., da Silva D.M., Asensi M.D. Occurrence of KPC-2-producing Klebsiella pneumoniae strains in hospital wastewater. J Hosp Infect 2011, 77:281.
22. Walsh T.R., Weeks J., Livermore D.M., Toleman M.A. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect Dis 2011, 11:355-362.
23. Girlich D., Bouihat N., Poirel L., Benouda A., Nordmann P. High rate of faecal carriage of extended-spectrum b-lactamase and OXA-48 carbapenemase-producing Enterobacteriaceae at a University hospital in Morocco. Clin Microbiol Infect 2014, 20:350-354.
24. Barguigua A., Zerouali K., Katfy K., El Otmani F., Timinouni M., Elmdaghri N. Occurrence of OXA-48 and NDM-1 carbapenemase-producing Klebsiella pneumoniae in a Moroccan university hospital in Casablanca, Morocco. Infect Genet Evol 2015, 31:142-148.
25. Zhao Z.C., Xu X.H., Liu M.B., Wu J., Lin J., Li B. Fecal carriage of carbapenem-resistant enterobacteriaceae in a Chinese university hospital. Am J Infect Control 2014, 42:e61-e64.
26. Moro M.L., De Toni A., Stolfi I., Carrieri M.P., Braga M., Zunin C. Risk factors for nosocomial sepsis in newborn intensive and intermediate care units. Eur J Pediatr 1996, 155:315-322.
27. Chemsi M., Chahid I., Lehlimi M., Aalloula O., Zerouali K., et al. Incidence des infections bacteriennes nosocomiales. Hôpital d'enfants Abderrahim Harouchi, CHU Ibn Rochd, Casablanca, Maroc. J Pediatr Puericult 2013, 26:11-18.
28. Dortet L., Cuzon G., Nordmann P. Dissemination of carbapenemase producing Enterobacteriaceae in France, 2012. J Antimicrob Chemother 2014, 69:623-627.
29. Potron A., Poirel L., Rondinaud E., Nordmann P. Intercontinental spread of OXA-48 b-lactamase-producing Enterobacteriaceae over a 11-year period, 2001 to 2011. Euro Surveill 2013, 18. [pii:20549].
30. Benouda A., Touzani O., Khairallah M.T., Araj G.F., Matar G.M. First detection of oxacillinase-mediated resistance to carbapenems in Klebsiella pneumoniae from Morocco. Ann Trop Med Parasitol 2010, 104:327-330.
31. Barguigua A., Zerouali K., Katfy K., El Otmani F., Timinouni M., Elmdaghri N. Occurrence of OXA-48 and NDM-1 carbapenemase producing Klebsiella pneumoniae in a Moroccan university hospital in Casablanca Morocco. Infect Genet Evol 2015, 31:142-148.
32. Wernli D., Haustein T., Conly J., Carmeli Y., Kickbusch I., Harbarth S. A call for action: the application of The International Health Regulations to the global threat of antimicrobial resistance. PLoS Med 2011, 8:e1001022.
33. Agence de la santé publique du Canada. Lignes directrices: mesures de prévention et de contrôle des infections à l'intention des travailleurs de la santé dans tous les établissements de soins de santé - Bacille Gram négatif résistant aux carbapénèmes: . http://www.phac-aspc.gc.ca/nois-sinp/guide/ipcm-mpci/ipcm-mpci-fra.php.